



September 28, 2018

Gene Techno Science Co., Ltd.

Code: 4584 (TSE Mothers)

Masaharu Tani, President & CEO

Submission of New Drug Application in Japan of Darbepoetin alfa Biosimilar

We(GTS) have been collaborating with Sanwa Kagaku Kenkyusho(SKK) based on collaborative research and development agreement for Darbepoetin alfa Biosimilar executed on January 21, 2014 and SKK submitted New Drug Application as of September 28, 2018.

Darbepoetin alfa is a long-acting erythropoiesis-stimulating agent that has been used for the treatment of anemia in chronic kidney disease patients on or not on dialysis stage and is widely used at a large number of medical institutions, and the innovator market size is around 50 billion yen in Japan.

SKK will sell this biosimilar after the approval and the profit will be allocated between SKK and us per SKK's sales revenue. By developing other biosimilars, we, as "Biotech Engineering Company, striving for value creation", continuously commit to create new drugs in order to provide new therapeutic options for the patients who cannot find out the best solution.

We expect the impact from this submission would have minimal impact on our FY2018 financial forecasts.